Desmoplastic small round cell tumor
MONDO:0019373Desmoplastic small round cell tumor (DSRCT) is an aggressive soft tissue cancer that typically arises in serous lined surfaces of the abdominal or pelvic peritoneum, and spreads to the omentum, lymph nodes and hematogenously disseminates especially to the liver. Extraserous primary location has been reported in exceptional cases.
Also known as: DSRCT, Desmoplas. small round cell tumor, Desmoplas. small round cell tumour, Desmoplastic small round cell tumor, Desmoplastic small round cell tumour, Desmoplastic small round-cell neoplasm, Desmoplastic small round-cell tumor, Desmoplastic small round-cell tumour
2837 clinical trials for this condition and its sub-types, 26 tagged with Desmoplastic small round cell tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New cocktail targets rare tumor in kids
Disease control OngoingThis early-phase trial adds three drugs—irinotecan, temozolomide, and bevacizumab—to the usual chemotherapy for newly diagnosed desmoplastic small round cell tumor (DSRCT), a rare and aggressive cancer. The study includes 15 patients aged 1 to 30 and aims to see if the combinatio…
Early phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Radioactive antibody targets rare childhood cancer
Disease control OngoingThis phase 2 trial tests a combination treatment for desmoplastic small round cell tumor (DSRCT), a rare cancer that often spreads in the abdomen. Participants receive a single dose of a radioactive antibody called 131I-omburtamab directly into the abdomen, followed by targeted r…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Experimental drug tazemetostat offered to patients with rare, aggressive tumors
Disease control Expanded access (ended)This expanded access program provides tazemetostat, a drug that blocks a protein called EZH2, to adults with serious or life-threatening solid tumors that have lost the INI1 or SMARCA4 protein. Eligible patients must have tried other treatments without success and cannot join a f…
Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Engineered immune cells take aim at childhood cancers in early trial
Disease control OngoingThis early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New radioactive drug targets childhood cancers that Won't quit
Disease control OngoingThis early-stage trial tests a radioactive drug called CLR 131 in 30 children and young adults with solid tumors, lymphoma, or brain tumors that have come back or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. P…
Phase 1 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Engineered immune cells take on childhood cancers in first human test
Disease control OngoingThis early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells (T cells) that are genetically modified to recognize and attack cancer cells ca…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC